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Abstract
Background: Multiple pharmacotherapy options are available to control blood glucose in Type 2 Diabetes Mellitus
(T2DM). Patients and prescribers may have different preferences for T2DM treatment attributes, such as mode and
frequency of administration, based on their experiences and beliefs which may impact adherence. As adherence is
a pivotal issue in diabetes therapy, it is important to understand what patients value and how they trade-off the
risks and benefits of new treatments. This study aims to investigate the key drivers of choice for T2DM treatments,
with a focus on injection frequency, and explore patients’ associated willingness-to-pay.
Methods: A discrete choice experiment (DCE) was used to present patients with a series of trade-offs between
different treatment options, injectable and oral medicines that were made up of 10 differing levels of attributes
(frequency and mode of administration, weight change, needle type, storage, nausea, injection site reactions,
hypoglycaemic events, instructions with food and cost). A sample of 171 Australian consenting adult T2DM
patients, of which 58 were receiving twice-daily injections of exenatide and 113 were on oral glucose-lowering
treatments, completed the national online survey. An error components model was used to estimate the relative
priority and key drivers of choice patients place on different attributes and to estimate their willingness to pay for
new treatments.
Results: Injection frequency, weight change, and nausea were shown to be important attributes for patients
receiving injections. Within this cohort, a once-weekly injection generated an additional benefit over a twice-daily
injection, equivalent to a weighted total willingness to pay of AUD$22.35 per month.
Conclusions: Based on the patient preferences, the importance of frequency of administration and other non-health
benefits can be valued. Understanding patient preferences has an important role in health technology assessment, as
the identification of the value as well as the importance weighting for each treatment attribute may assist with funding
decisions beyond clinical trial outcomes.
Keywords: Discrete choice experiment, Diabetes, Willingness to pay, Patient preference, Consumer surplus,
Reimbursement, Health technology assessment
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Background
Type 2 Diabetes Mellitus (T2DM) is a progressive condi-
tion in which a person’s body becomes resistant to the
normal effects of insulin and/or slowly loses the ability
to produce enough insulin in the pancreas causing eleva-
tions in blood glucose [1]. Worldwide it is estimated that
422 million people are living with diabetes or approxi-
mately 8.5% of the adult population [2]. In Australia,
approximately 849,000 (4.7%) of adults aged 18 years are
estimated to have T2DM, a higher rate among men than
women, estimated at 5.4% versus 4.2% in 2016 [3]. The
disease is associated with risk factors such as blood pres-
sure, high cholesterol and coagulation. More seriously, it is
also associated with reduced life expectancy and quality of
life, driven by significant morbidity due to microvascular
and macrovascular complications [4, 5].
Although there is no cure for T2DM, treatments typi-
cally use multiple interventions. Common treatment ap-
proaches focus on lifestyle modification followed by
various pharmacotherapy options selected on the basis
of individual clinical circumstances [6]. Optimising
blood glucose control is necessary to improve both
short- and long-term health outcomes in patients with
T2DM. Those patients with uncontrolled or poor gly-
caemic control on one or more oral glucose-lowering
agents may be treated with injectable treatments such as
insulin and/or glucagon-like peptide-1 agonists (GLP-1
agonists). In Australia, prescribers have multiple treat-
ment options to control their patient’s blood glucose, in-
cluding oral and injectable treatments. These treatments
play a vital role in the management of T2DM, control-
ling symptoms, preventing complications and improving
health outcomes [5].
In respect to treatment, adherence remains a pivotal
issue, with rates of adherence ranging from 36 to 93%
among patients [7]. The determinants of non-adherence
fall into the following categories: patient factors, treat-
ment regimen, disease factors, prescriber-level factors
(including patient-physician relationship), and the clin-
ical setting. All evidence suggests the determinants of
non-adherence in T2DM patients are consistent with
other chronic conditions, although some may argue that
insulin use is associated with unique barriers given its
requirement for subcutaneous injection [8, 9]. As such,
understanding patients’ preferences for the attributes of
treatments, particularly mode and frequency of adminis-
tration, and their relative importance to patients may
result in tailored therapeutic decisions by prescribers that
improve patient adherence, provide greater patient satis-
faction and ultimately better health outcomes [10, 11].
The substantial body of research on patients’ treat-
ment preferences into T2DM adult patients utilises a
variety of methodologies such as discrete choice ex-
periments (DCEs) [12], qualitative research [13],
contingent valuation [14], revealed preference [15],
time trade-off and other types of ranking and rating
techniques [16]. Discrete choice experiments are a
sophisticated way to assess the desirability and value
of different attributes that do not exist in real
markets as well as new alternatives. Previous patient
preference literature has predominantly focused on at-
tributes including efficacy, dosing schedule, glucose
control, body weight change, and adverse events such
as nausea and hypoglycemia [17, 18]. Although a few
studies have focused on differing modes of adminis-
tration, few have considered a cost attribute to deter-
mine patients’ willingness to pay for specific
treatment attributes [12, 17, 19].
Thus, the aim of this study was to investigate the key
drivers of choice for T2DM treatments, with a focus on
valuing injection frequency and mode of administration,
and to explore patient willingness to pay (WTP) for the
different attributes of these treatments. Identifying
patients’ preferences for these attributes may provide a
basis for valuing the non-health benefits, aid in clinical
decision-making as well as funding and reimbursement
decisions.
Methods
The study focused on the development of a choice model-
ling approach designed to gain an understanding of the
treatment preferences of patients currently taking either
twice-daily injectable exenatide (Byetta®) or oral glucose-
lowering medicines in comparison to hypothetical new
treatments. The study did not receive formal ethics
approval as the online survey research did not impose, or
was considered of minimal risk to participants, and only
enrolled competent adults.
Discrete choice experiment
The central feature of the study was the discrete choice
experiment. DCEs were first developed in the late 1920s
allowing for comparisons of two alternatives and later
extended through theory and modelling from the1960s
[20–22]. DCEs are now used in many fields to under-
stand and model the trade-offs and preferences revealed
by the choices that people make. Examples of the use of
DCE methods include determining the rate of uptake for
vaccinations prior to the vaccine going to market,
community preferences for alternative policies on redu-
cing smoking, and the valuation of alternative drug
treatments.
Survey instrument
The research involved the development of a survey
with DCE. The attributes and levels of the DCE
(Table 1) were based on previous qualitative research
provided, an interrogation of patient preference
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literature, evidence from clinical trials of exenatide
and consultation with external advisers (health eco-
nomics and medical experts) and clinicians.
The survey instrument consisted of seven sections
(Table 1 broadly covering treatment experiences,
satisfaction, quality of life, work productivity and
preferences for treatment. The DCE component for
the injectable cohort offered three hypothetical alter-
natives of treatment (either injectable or oral), plus a
status quo alternative (exenatide) (Fig. 1). The oral
cohort experiment was structured the same way
except without the status quo alternative (Fig. 2).
Respondents in each cohort were shown multiple
hypothetical scenarios requiring them to select their
preferred option from a set of competing alternatives
(choice tasks). The features of the alternatives were
then systematically varied, allowing for a determin-
ation of how each of the features impacts upon the
preferences of each cohort. Participants each com-
pleted eight choice tasks which were randomised
across participants.
A pilot study with 10 patients from each cohort
were conducted prior to launching the main field
phase to determine whether any changes to the con-
tent or design of the DCE were required. No changes
were made to the overall survey and DCE as partici-
pants reported the attributes were relevant and the
survey easy to understand.
Study sample
For this study, the sample was stratified by current
treatment to form two patient cohorts: 1) current
patients using injectable exenatide treatment and 2)
current patients on oral glucose-lowering medicines.
A target sample size of a minimum 50 patients in
each cohort was required to allow for sub-group ana-
lyses. To be eligible for the study, patients met the
following criteria: 18 years of age or older, diagnosed
with T2DM and on medicine for their T2DM, either
injectable exenatide or oral glucose-lowering
medicines.
Participants were mainly recruited through online
panel providers as consumer panels are a cost effect-
ive and efficient way to recruit respondents nationally
for online projects. Participants completed the survey
in November 2014 and received reward points from
the online panel provider. Supplementary recruitment
was undertaken through advertising in local newspa-
pers in capital cities to target eligible patients with
T2DM. Interested patients were provided with contact
details to enroll in the study.
Willingness to pay
The literature identifies two primary types of WTP
measures that can be derived from models of discrete
choice; marginal WTP and total WTP. In this study,
we concentrated on total WTP (also known as
consumer surplus) which is the monetary representa-
tion of utility, or satisfaction-based economic value,
Table 1 An Overview of the Key Attributes
Attributes Attribute levels












Shorter / thinner (between a faint pain
sensation and no pain sensation)
Longer / thicker (a very weak pain sensation)








Multi use pen (no mixing required)
Multi use pen (some mixing required)
Single use pen (no mixing required)
Single use pen (some mixing required)
Vial and syringe (no mixing required)













plus 60% (100% for oral)
plus 45% (75% for oral)
plus 30% (50% for oral)







Taken / used within a certain time of
eating
Taken / used anytime (unrestricted)
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accruing to the community. Accordingly, total WTP
captures the additional benefits an alternative brings
to a market and is often interpreted as the total value
of the alternative. For example, the value of
non-health outcomes (e.g. frequency or mode of
administration) in supplementary cost-benefit analysis
presented to regulatory / healthcare governing bodies
[23, 24]. Thus, the change in total willingness to pay
(or consumer surplus) is a comparison of two scenar-
ios (e.g. market or policy changes etc.), drawn from
Fig. 1 Example choice task for participant using exenatide
Fig. 2 Example choice task for participant taking oral glucose-lowering medicine
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the DCE [25]. This approach employs the definition
offered by Train (2009 p. 56), shown in eq. (1).

















is the exponential of the part-worth utility
(hereinafter referred to as utility) for the new alternative,
eV
Current
is the exponential of the utility for the current
alternative and βCost is the parameter for cost.
Applied to patients with T2DM in this study, the total
WTP calculated represents the additional value this
group of patients gains through improvements in new
treatments compared to current treatments.
Statistical analysis
Descriptive statistics were performed for each of the
patient cohorts using SPSS. The combinations of levels
for each attribute in the DCE were designed using the
latest experimental techniques developed by Rose and
Bliemer [26]. A Bayesian D-efficient design with basic
priors to account for the direction of each parameter
was used to structure the DCE and implemented in
NGene version 1.1.2 (ChoiceMetrics Pty Ltd), a software
tool used to generate stated choice experimental design.
Bayesian efficient designs allow researchers to estimate
suitable models with smaller sample sizes. All models
were estimated using the specialised choice analysis soft-
ware Nlogit 5.0 (Econometric Software Inc., NY, USA).
Whilst the simplest discrete choice model is called the
Multinomial Logit model (MNL), this has certain restric-
tive assumptions related to error terms, independence of
observed choices and homogeneity of preferences [22].
More advanced models such as the Error Components
(EC) model, used to estimate the model in this study,
allow for the easing of some of these assumptions [27]. As
such, the EC model is a more flexible and superior model,
allowing for correlation in the errors of the alternatives
(assumption that errors are independently and identically
distributed) and repeated choice observations (assumption
that all observations are treated as independent even if
they are from the same respondent).
Alternative specific parameters were estimated for in-
jectable and oral treatments in this model. Further,
different cost parameters were permitted to account for
variation in price ranges based on concession status.
Separate error components were estimated for the
injectable alternatives [28]. Variables that were not sig-
nificant were removed for the final model.
Results
A total of 171 adult patients with T2DM completed an
online survey in November 2014 assessing their prefe-
rence for T2DM treatments and their willingness to pay
for the different features of these treatments. Of those
that completed the online survey, 153 were recruited
through online panels and 18 through advertising. The
study participants included 58 patients receiving
twice-daily injections (injectable cohort) and 113
patients on oral treatments (oral medicine cohort). The
sample size obtained was sufficient to estimate the
models applied in this study given the attributes and
levels in the experimental design.
Descriptive statistics of the patient characteristics for
each of the two patient cohorts are presented in Table 2.
The sample characteristics were similar across both
cohorts with the exception of the oral medicine cohort
being slightly older and more often entitled to a conces-
sional rate for their medicines. The overall sample con-
sisted of a greater percentage of males than females and
the majority (78%) of participants were over 50 years of
age. Almost half of all participants had a household in-
come of $72,999 and under. Given the age of the study
sample, this may suggest participants were retired and/
or on an old-age pension.
EC model outputs
The model results are shown in Table 3 below. Due to
the small sample sizes, the exenatide and oral medicines
patient samples were pooled and differences between
these patient segments were tested using interaction
terms. Alternative specific parameter estimates were es-
timated for both injection and oral treatments. Insignifi-
cant parameters (p > 0.05) were removed from the final
DCE model. The model fit results illustrate that the
model provided a superior fit to a constant only model.
Main effects are estimated for both injectable and oral
alternatives.
The model results suggest that patients are mainly
concerned with frequency, weight changes and nausea.
Interaction effects (i.e. test for differences in preferences
between injectable and oral patient sample) are also in-
cluded. Oral patients are more concerned about weight
changes and intuitively more likely to choose oral
treatments.
Relative attribute importance
In standard choice models, the parameters cannot typi-
cally be directly compared because the variables they are
related to are presented on different scales, meaning the
parameters also reflect different scales (e.g., the range of
the cost attribute compared to other attributes). In this
case, the attributes were multi-level categorical coded, so
the magnitude of the parameter reflects the influence on
utility. A Decision Support System (DSS) was used to
further evaluate the importance of bundles of attributes
by changing treatment combinations and observing the
change in willingness to pay.
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The top three attributes of importance were the same
for patients in the injectable and oral medicine cohorts.
These were in rank order: (i) weight change, (ii) fre-
quency of administration and (iii) nausea. For patients
using injectable exenatide, hypoglycaemic events per
month ranked fourth, however this was non-significant
in the oral medicine cohort. All other attributes were
not significant.
Willingness to pay
In this study, total WTP was calculated by comparing
the utility difference (as per eq. 1) in two scenarios based
on injection frequency differences. In these calculations
the current scenario treatment was a twice-daily injec-
tion and the new scenario treatment was a once-weekly
injection, which resulted in a weighted total WTP of
$22.35 per month, holding all other attributes constant.
Table 2 Background Socio-demographics
Overall (n = 171)
N,%
Injectable patients (n = 58) N,% Oral patients (n = 113) N,%
Gender
Male 104 (60.8) 37 (63.8) 67 (59.3)
Female 67 (39.2) 21 (36.2) 46 (40.7)
Age
18–29 years 4 (2.3) 3 (5.2) 1 (0.9)
30–39 years 10 (5.8) 8 (13.8) 2 (1.8)
40–49 years 24 (14.0) 8 (13.8) 16 (14.2)
50–59 years 48 (28.1) 19 (32.8) 29 (25.7)
60–69 years 64 (37.4) 17 (29.3) 47 (41.6)
70 years and over 21 (12.3) 3 (5.2) 18 (15.9)
Household income
$Nil-$33,799 ($0–$649 a week) 35 (20.5) 7 (12.1) 28 (24.8)
$33,800–$72,999 ($650–$1399 a week) 47 (27.5) 23 (39.7) 24 (21.2)
$72,800–$129,999 ($1400–$2499 a week) 45 (26.3) 15 (25.9) 30 (26.5)
$130,000–$181,999 ($2500–$3499 a week) 13 (7.6) 6 (10.3) 7 (6.2)
$182,000 or more ($3500 or more a week) 5 (2.9) 2 (3.4) 3 (2.7)
Prefer not to answer 26 (15.2) 5 (8.6) 21 (18.6)
Household composition
Couple family with no children 60 (35.1) 15 (25.9) 45 (39.8)
Couple family with children 44 (25.7) 19 (32.8) 25 (22.1)
One parent family 6 (3.5) 2 (3.4) 4 (3.5)
Other family 5 (2.9) 1 (1.7) 4 (3.5)
Single person household 40 (23.4) 17 (29.3) 23 (20.4)
Group household (i.e., shared) 16 (9.4) 4 (6.9) 12 (10.6)
State
ACT 4 (2.3) 2 (3.4) 2 (1.8)
NSW 77 (45.0) 22 (37.9) 55 (48.7)
VIC 41 (24.0) 19 (32.8) 22 (19.5)
QLD 18 (10.5) 4 (6.9) 14 (12.4)
SA 17 (9.9) 7 (12.1) 10 (8.8)
WA 10 (5.8) 1 (1.7) 9 (8.0)
TAS 3 (1.8) 3 (5.2) 0 (0.0)
NT 1 (0.6) 0 (0.0) 1 (0.9)
Patient type
General Patient 89 (52.0) 36 (62.1) 53 (46.9)
Concessional Patient 82 (48.0) 22 (37.9) 60 (53.1)
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Table 3 Model Output for T2DM
Main effects Injectable treatment Oral treatment
Parameter t-ratio Parameter t-ratio
Frequency
Once a month 1.449 9.39 1.421 8.77
Once a week 1.192 8.05 1.374 7.5
Once a day N/S N/S 0.597 3.09
Twice a day reference reference reference reference
Weight change (% body weight)
Lose 10% 0.698 8.62 2.257 1051
Lose 5% 1.217 8.61 1.737 7.48
None 1.450 3.73 0.582 2.11
Gain 5% reference reference reference reference
Needle you use to inject
Longer / thicker (very weak pain sensation) N/S N/S N/A N/A
Shorter / thinner (faint pain sensation) reference reference reference reference
Storage
Keep in the fridge until first use N/S N/S N/S N/S
No refrigeration required reference reference reference reference
Nausea
None 0.641 3.74 0.610 3.93
Mild 0.368 2.14 0.273 1.65
Moderate reference reference reference reference
Mode of administration (device)
Multi use pen N/S N/S N/A N/A
Single use pen N/S N/S N/A N/A
Single use vial and syringe reference reference reference reference
Injection site reactions / nodules
Yes N/S N/S N/A N/A
No reference reference reference reference
Hypoglycaemic events per month
0 0.521 3.11 N/S N/S
1 N/S N/S N/S N/S
2 N/S N/S N/S N/S
> 2 reference reference reference reference
Instructions with eating
Taken / used within a certain time of eating N/S N/S N/S N/S
Taken / used anytime (unrestricted) reference reference reference reference
Cost
Cost (General) −0.015 2.27 −0.029 −7.25
Cost
Cost (Concession) N/S N/S −0.267 −4.6
Interaction effects (oral sample)
Weight change * (oral)
Lose 10% N/S N/S
Lose 5% 1.239 4.24
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The $22.35 total WTP can be interpreted as a monetary
measure of the additional benefit or utility that patients
gain from moving from a twice-a-day injection (current
exenatide treatment) to a once-weekly injection (new
treatment).
Decision support system
A DSS was developed to support the visualisation of the
model results. This enables the user (e.g., pharmaceutical
company or clinician) to perform ‘what if ’ scenarios
based on hypothesised changes to the treatments, such
as to frequency or side effects. In this research, willing-
ness to pay or consumer surplus was a main outcome of
interest in support of a reimbursement application. In
Australia, the Pharmaceutical Benefits Advisory Com-
mittee guidelines allow for supplementary analysis where
a medicine may have a direct patient benefit that is not
a health outcome – as in this case, providing a more
convenient form of administration to the patient.
The DSS was designed to reflect two dimensions of
the injectable market - willingness to pay calculations
for patients on injectable (current treatment) and for
those moving to an alternative injectable treatment (new
treatment). The results derived from this type of model
may assist industry to better understand what patients
value or prefer when developing new treatments as well
as guide clinicians when making decisions about which
treatment to prescribe.
The DSS was constructed in flash (presented as a pdf
file) and provided a simple user interface. A snapshot of
the Decision Support System is shown in Fig. 3.
Discussion
The use of discrete choice experiments in reimburse-
ment submissions is not new in Australia, with Davey et
al. 1998 [29] successfully using WTP for insulin lispro,
and the Pharmaceutical Benefits Advisory Committee
(PBAC) rejecting a WTP claim for Victoza (liraglutide)
based on a Scandinavian study by Jendle et al. 2012 [30].
As such, this study investigated the key drivers of choice
for T2DM treatments for Australian patients and was
designed for presentation to the PBAC as part of the
exenatide 2 mg once-weekly (Bydureon) reimbursement
dossier.
Bydureon is an extended release microspheres formula-
tion of exenatide, which has been listed on the PBS since
2010 in the twice-daily form (Byetta). Bydureon signifi-
cantly reduces injection frequency versus Byetta from two
per day to one per week, but had not been listed on the
Pharmaceutical Benefits Scheme (PBS) despite three reim-
bursement submissions across 2011 to 2013. This absence
on the PBS was in part due to the reimbursement system
in Australia, where under the National Health Act, the
PBAC cannot grant price premiums for medicines without
a significant improvement in efficacy or reduction of
toxicity over the alternative therapy.
In the PBAC submission, it was argued that the
availability of a once-weekly injectable medicine for
T2DM would improve adherence and therefore blood
glucose levels and long-term outcomes, particularly in
Aboriginal and Torres Strait Islander people who are
almost four times more likely than non-Indigenous
Australians to have diabetes or pre-diabetes [31].
However, a data gap existed as the participants and
circumstances of use in the clinical studies were not
sufficiently representative of the proposed population
and were unlikely to provide surety to the PBAC that
adherence and outcomes would be improved.
Our research demonstrated the importance to Australian
patients of a reduced injection frequency, with the con-
sumer surplus considered a surrogate for adherence. The
PBAC recommended Bydureon on the basis of potential
Table 3 Model Output for T2DM (Continued)
Main effects Injectable treatment Oral treatment
Parameter t-ratio Parameter t-ratio
None 0.848 3.03
Gain 5% reference reference
Cost (concession) * (oral)
Cost * sample 0.207 3.48
Sample (oral) constant 1.216 2.93
Constant
Oral constant (concession) 1.816 3.52
Error components
Injectable alternative (General) 1.446 6.36
Injectable alternative (Concession) −2.545 6.56
Log likelihood (c): - 1438; Log likelihood (β): − 1031; Rho squared: 0.28; Number of respondents: 171; Number of choice observations: 1368
Abbreviations: N/S (Not Significant), N/A (Not Applicable)
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health benefits from likely improved adherence by a small
number of high clinical need populations. Bydureon was
subsequently listed on the PBS and greater than fifteen
thousand patients now access Bydureon for treatment of
their T2DM [32, 33].
This positive recommendation reaffirms the value of
local and applicable research in Australian reimbursement
submissions, and the increasing importance of providing a
voice for the patient during funding decisions.
As with all studies, there are limitations and the re-
sults should be interpreted within the context of these
limitations. Firstly, as the survey was conducted online,
a number of inherent limitations exist. Literacy and lan-
guage skills were not tested and participants may not
have had an adequate understanding of the choice tasks.
To adjust for this, a pilot was conducted online with a
sample of patients using targeted feedback and adjust-
ments made to ensure logic and understanding. Partici-
pants who completed the final survey under a certain
time limit, and/or clicked the same response or pattern
of responses through the choice tasks, or scored below a
certain mark on question regarding understanding of the
task were removed from the analysis. Secondly, the diag-
nosis was not verified by a clinician, and relied on
self-reporting by participants. Blinded screening ques-
tions (disease and medication based) were incorporated
to ensure only patients with a genuine diagnosis meeting
the eligibility criteria participated. Nonetheless, the final
sample may not accurately represent the diabetes
population. Lastly, patients were asked to evaluate
certain hypothetical treatment scenarios, which may not
necessarily reflect the choices they would make in a real
setting.
Conclusion
This study aimed to investigate the key drivers of choice
for type 2 diabetes treatments. A sample of 171 patients
(including 58 exenatide patients and 113 oral medicines
patients) completed an online survey using state of art
choice experiments. In the survey patients were asked to
trade off both injectable and oral treatments with diffe-
rent features to ascertain what was most important to
them. The most important features of treatment to both
exenatide and oral glucose-lowering medicines patients
were weight change, frequency and nausea. It is not sur-
prising that weight gain was a key driver of participant
choice. Many diabetic patients struggle with their weight
and are often actively encouraged to lose weight as part
of their disease management. However, often the use of
antidiabetic medications are associated with weight gain,
which may conflict patients (and impact adherence) and
complicate diabetes management.
The results were integrated into a Decision Support
System that enables stakeholders to perform scenario ana-
lysis. The scenarios presented for the different markets
(injectable and oral) measured total willingness to pay
(consumer surplus) as a main outcome. The injectable
market findings suggest that once-weekly injectable treat-
ment generates an additional benefit over the current
treatment twice-daily injectable exenatide, equivalent to a
weighted willingness to pay of $22.35 per month. Similar
calculations are presented for the oral market. Intuitively,
Fig. 3 Decision Support System
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the oral market results show oral treatments are strongly
preferred to injectable testaments.
These findings may provide guidance for clinicians
making therapeutic decisions regarding T2DM treatments
and provide a better understanding of what patients prefer
and value in their treatment. This study shows that
patients highly value the avoidance of injections, with
once-weekly dosing clearly preferred over twice-daily
dosing. Of the other attributes, weight loss is preferred, as
is the avoidance of nausea. Consideration of patient pre-
ference is important when making therapeutic decisions
and can improve health outcomes. This type of analysis
has a role in health technology assessment and has been
presented to PBAC during their assessment of new
therapies.
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